KEGG   DRUG: Anrukinzumab
Entry
D08857                      Drug                                   
Name
Anrukinzumab (USAN)
Formula
C6452H9954N1714O2024S46
Exact mass
145301.5817
Mol weight
145391.3306
Sequence
(A chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFI SYAMSWVRQA PGKGLEWVAS ISSGGNTYYP
DSVKGRFTIS RDNAKNSLYL QMNSLRAEDT AVYYCARLDG YYFGFAYWGQ GTLVTVSSAS
TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPEALGAPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGK
(B chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFI SYAMSWVRQA PGKGLEWVAS ISSGGNTYYP
DSVKGRFTIS RDNAKNSLYL QMNSLRAEDT AVYYCARLDG YYFGFAYWGQ GTLVTVSSAS
TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPEALGAPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGK
(C chain)
DIQMTQSPSS LSASVGDRVT ITCKASESVD NYGKSLMHWY QQKPGKAPKL LIYRASNLES
GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQSNEDPW TFGGGTKVEI KRTVAAPSVF
IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
(D chain)
DIQMTQSPSS LSASVGDRVT ITCKASESVD NYGKSLMHWY QQKPGKAPKL LIYRASNLES
GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQSNEDPW TFGGGTKVEI KRTVAAPSVF
IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
(Disulfide bridge: A22-A95, A145-A201, A221-C218, A227-B227, A230-B230, A262-A322, A368-A426, B22-B95, B145-B201, B221-D218, B262-B322, B368-B426, C23-C92, C138-C198, D23-D92, D138-D198)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Efficacy
Antiasthmatic, Anti-IL-13 antibody
Comment
Monoclonal antibody
Treatment of asthma
Target
IL13 [HSA:3596] [KO:K05435]
Brite
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D08857  Anrukinzumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL13
     D08857  Anrukinzumab (USAN)
Other DBs
CAS: 910649-32-0
PubChem: 96025540
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system